Clinical trials: Brain Metastases From Solid Tumors
Brain Metastases, Generalized Malignancy, Primary
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in…
- Conditions
- Brain Metastases, Generalized Malignancy, Primary, Brain Lesions
- Trial name
- NCT02187822
- Testing
- TPI 287, Fractionated Stereotactic Radiotherapy (FSRT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastases
Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
This type of study is called a "Phase I study". Its purpose is to determine the side effects of the two medicines listed in this study when given together with whole brain radiation, and the highest dose of valproic acid that can…
- Trial name
- NCT00437957
- Testing
- Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain Metastases From Solid Tumors
Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:
This study is a multicenter, open label, randomized controlled, adaptive phase II/III seamless design clinical trial aimed at comparing the efficacy and safety of methylprednisolone (MP) and dexamethasone (DEX) in the treatment…
- Trial name
- NCT07542288
- Testing
- Methylprednisolone (Corticosteroid), Dexamethasone
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Second Affiliated Hospital of Hainan Medical University
Brain Metastases From Solid Tumors
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid…
- Trial name
- RAD101 (NCT06777433)
- Testing
- RAD101 (18F-FPIA)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00837928
- Testing
- bendamustine, laboratory biomarker analysis, Surgical Resection of Brain Metastases
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- John Grecula
Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
The goal of this phase II clinical trial] is to analyze the efficacy of patritumab deruxtecan (HER3-DXd) in patients with metastatic breast cancer (MBC) or advanced non-small cell lung cancer (aNSCLC) with active brain metastases…
- Conditions
- Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult
- Trial name
- TUXEDO-3 (NCT05865990)
- Testing
- Patritumab deruxtecan
- Where
- 8 sites in Austria, Spain
- Volunteers
- 63 people
- Sponsor
- MedSIR
Brain Metastases
Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
Investigators designed a study of a multimodality approach: surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach for patients with single, large brain metastases from solid primary…
- Trial name
- NCT02576522
- Testing
- brain metastatic patients
- Where
- Italy
- Volunteers
- 87 people
- Sponsor
- Istituto Clinico Humanitas
Brain Metastases From Solid Tumors, Leptomeningeal Disease
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor…
- Conditions
- Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM)
- Trial name
- NCT07751744
- Testing
- JBI-778
- Volunteers
- 113 people
- Sponsor
- Jubilant Therapeutics Inc.
Recurrent Brain Metastases, Progressive Brain Metastases
Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary
Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory.
- Trial name
- NCT02429570
- Testing
- Meclofenamate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Metastases
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
The purpose of this study is to: Test the maximum tolerated dose (MTD) of Bendamustine with whole brain radiation therapy (WBRT) To determine the plasma pharmacokinetics (a blood test to see how much of the drug is getting into…
- Trial name
- NCT00879073
- Testing
- Bendamustine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Glioblastoma, Brain Metastases
Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study
An open-label, single institutional phase II trial of losartan in patients with primary and metastatic brain tumors with an individual stepped-wedge, randomized, assessor-blinded, dose-finding design on three indications.
- Trial name
- ImPRESS (NCT03951142)
- Testing
- Losartan
- Where
- Norway
- Volunteers
- 165 people
- Sponsor
- Kyrre Eeg Emblem
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children
- Trial name
- NCT00389584
- Testing
- irinotecan hydrochloride, cognitive assessment, management of therapy complications
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals